These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18626573)

  • 1. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography.
    Gelovani JG
    Cancer Metastasis Rev; 2008 Dec; 27(4):645-53. PubMed ID: 18626573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.
    Abourbeh G; Dissoki S; Jacobson O; Litchi A; Ben Daniel R; Laki D; Levitzki A; Mishani E
    Nucl Med Biol; 2007 Jan; 34(1):55-70. PubMed ID: 17210462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
    Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
    J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging EGFR and HER2 by PET and SPECT: a review.
    Corcoran EB; Hanson RN
    Med Res Rev; 2014 May; 34(3):596-643. PubMed ID: 24037872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
    Pal A; Glekas A; Doubrovin M; Balatoni J; Namavari M; Beresten T; Maxwell D; Soghomonyan S; Shavrin A; Ageyeva L; Finn R; Larson SM; Bornmann W; Gelovani JG
    Mol Imaging Biol; 2006; 8(5):262-77. PubMed ID: 16897320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer.
    Mishani E; Hagooly A
    J Nucl Med; 2009 Aug; 50(8):1199-202. PubMed ID: 19617320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
    Wang JQ; Gao M; Miller KD; Sledge GW; Zheng QH
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4102-6. PubMed ID: 16697188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
    Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E
    Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor inhibitors: a patent review (2010 - present).
    Li SN; Li HQ
    Expert Opin Ther Pat; 2014 Mar; 24(3):309-21. PubMed ID: 24387079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the epidermal growth factor receptor in solid tumor malignancies.
    Nedergaard MK; Hedegaard CJ; Poulsen HS
    BioDrugs; 2012 Apr; 26(2):83-99. PubMed ID: 22385404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
    Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
    Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.